Artificial intelligence in oncological imaging screening.
1/5 보강
The global cancer burden continues to escalate, driven by a significant rise in new cases and cancer-related deaths.
APA
Guo Z, Xu M, et al. (2026). Artificial intelligence in oncological imaging screening.. International journal of surgery (London, England), 112(2), 4401-4417. https://doi.org/10.1097/JS9.0000000000003858
MLA
Guo Z, et al.. "Artificial intelligence in oncological imaging screening.." International journal of surgery (London, England), vol. 112, no. 2, 2026, pp. 4401-4417.
PMID
41287865 ↗
Abstract 한글 요약
The global cancer burden continues to escalate, driven by a significant rise in new cases and cancer-related deaths. Early detection through effective screening programs is paramount for reducing mortality, and the integration of Artificial Intelligence (AI) into oncological imaging has shown transformative potential. This review comprehensively examines the evolution and clinical application of AI in oncological imaging for cancer detection across various modalities, including ultrasound, X-ray, computed tomography, magnetic resonance imaging, and endoscopy, highlighting significant advancements in early cancer screening. We further address the challenges associated with AI implementation in medical imaging, including dataset bias, the need for robust regulatory frameworks, and technical integration barriers. Emphasis is placed on the necessity of standardized, diverse datasets, explainable algorithms, and equitable implementation to mitigate disparities. By aligning technological innovation with rigorous clinical validation, ethical governance, and seamless workflow integration, AI is poised to revolutionize cancer care through earlier and more accurate detection, personalized risk stratification, and ultimately, improved patient outcomes.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Discovery of novel and potent 2-aminopyrazine-based HPK1 inhibitors enhancing T-cell immunity against cancer.
- RASGEF1B suppresses hepatocellular carcinoma through the ALDH7A1/Betaine/SNAI1 metabolic‒epigenetic axis.
- Mitochondria Pathway Signature Predicts Prognosis and Therapeutic Response and Identifies REXO2 as a Crucial Regulator in Breast Cancer.
- The microbial metabolite I3A inhibits ferroptosis and the effectiveness of redox-based cancer therapy.
- Correction: Guo et al. Shikonin as a WT1 Inhibitor Promotes Promyeloid Leukemia Cell Differentiation. 2022, , 8264.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.